APA (7th ed.) Citation

Meisel, A., Kassem, Z., Turek, D., Gradistanac, T. A., Lage, T. d., & Züger, C. (2025). Tafasitamab and Lenalidomide as Second-Line Treatment in an Elderly Patient with a Primary Refractory Double-Hit Diffuse Large B-Cell Lymphoma. THE HEALTHBOOK COMPANY LTD.

Chicago Style (17th ed.) Citation

Meisel, Alexander, Ziad Kassem, Daniel Turek, Tanja Angelina Gradistanac, Tristan de Lage, and Christina Züger. Tafasitamab and Lenalidomide as Second-Line Treatment in an Elderly Patient with a Primary Refractory Double-Hit Diffuse Large B-Cell Lymphoma. THE HEALTHBOOK COMPANY LTD, 2025.

MLA (9th ed.) Citation

Meisel, Alexander, et al. Tafasitamab and Lenalidomide as Second-Line Treatment in an Elderly Patient with a Primary Refractory Double-Hit Diffuse Large B-Cell Lymphoma. THE HEALTHBOOK COMPANY LTD, 2025.